Q2 2024 Earnings Estimate for Cresco Labs Inc. (OTCMKTS:CRLBF) Issued By Wedbush
Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Equities research analysts at Wedbush lowered their Q2 2024 earnings per share estimates for Cresco Labs in a report released on Thursday, May 16th. Wedbush analyst G. Pascarelli now anticipates that the company will earn ($0.04) per share for the quarter, down from their prior estimate of ($0.03). Wedbush has a “Outperform” rating and a $3.00 price target on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.05) per share. Wedbush also issued estimates for Cresco Labs’ Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.11) EPS. Several other equities analysts have also weighed in on CRLBF. Needham & Company LLC reaffirmed a “hold” rating on shares of Cresco Labs in a research report on Thursday. Roth Mkm lifted their price target on shares of Cresco Labs from $1.75 to $2.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. Finally, Echelon Wealth Partners raised shares of Cresco Labs from a “hold” rating to a “buy” rating in a research report on Wednesday, March 13th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $2.63. Check Out Our Latest Stock Report on CRLBF Cresco Labs Price Performance Shares of CRLBF opened at $2.16 on Monday. The firm has a market cap of $746.54 million, a PE ratio of -4.60 and a beta of 2.08. The firm’s 50 day moving average price is $2.07 and its 200 day moving average price is $1.84. The company has a debt-to-equity ratio of 1.55, a quick ratio of 0.85 and a current ratio of 1.39. Cresco Labs has a twelve month low of $1.00 and a twelve month high of $2.77. Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). The firm had revenue of $184.30 million for the quarter, compared to analyst estimates of $183.31 million. Cresco Labs had a negative net margin of 20.32% and a negative return on equity of 6.61%. About Cresco Labs (Get Free Report) Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
May 20, 2024 | www.defenseworld.net